Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
|Poll|December 27, 2021
POLL: Do You Have Access to the iPLEDGE Program?
Author(s)Dermatology Times Staff
Don't Forget to take this week's poll.
Advertisement
With the issues starting on December 13, many still have issues accessing the iPLEDGE website and customer service. Have you gotten access to the iPLEDGE program?
Advertisement
Related to this article
Dermatology Times is looking back on the top stories in dermatology from the month of October.
From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.
Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.
The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
Advertisement
Advertisement